MA-ULTIVUE
15.3.2022 16:02:09 CET | Business Wire | Press release
Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, and Sirona Dx, a technical contract research organization (CRO), providing advanced, single cell proteomics and genomics services to accelerate the pace of immunotherapy and targeted therapy development, announced a co-marketing agreement to deliver tissue-based spatial multiplexed immunophenotyping solutions for translational research groups and Biopharma.
Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique solutions for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics. Its proprietary InSituPlex® technology, designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in precious tissue samples combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology. “Our InSituPlex technology offers valuable profiling of the tissue and expands the depth of information possible from a single section that is complementary to the high-parameter capabilities offered by Sirona Dx. We believe this joint offering will now provide researchers a seamless workflow enabling a far more efficient biomarker discovery and drug development process.” said Mark Rees, Ph.D. Vice President Corporate Development at Ultivue.
Sirona Dx are original pioneers of spatial biology, having launched ultra-high parameter, multiplexed imaging services to Biopharma in 2018. Their technology agnostic, full service, spatial biology suite, contributed to their selection as a Top 10 CRO of 2021 by Medhealth Outlook.
“We are delighted to announce this partnership with Ultivue” said Andrew Brown, Ph.D. Chief Commercial Officer at Sirona Dx. “Since 2018, clients have relied on our leading expertise to develop and implement customized, high performance multiplexed imaging panels of up to 40 markers. Having cast a wide net to identify the most informative tissue biomarker signatures, we can now harness Ultivue’s powerful InSituPlex® technology to rapidly develop, robustly validated mid-plex panels of up to 12 markers enabling our clients to accelerate their drug development programs with transformative biomarker capabilities.
About Sirona Dx
Sirona Dx is a technical CRO, founded to accelerate the pace of immunotherapy and targeted therapy development. Bridging silos between diagnostics manufacturers and translational clinical research our laboratory offers specialized high complexity, single cell proteomics and genomics services supporting pharmaceutical companies with their drug discovery and development programs. Learn more at Sironadx.com.
About Ultivue
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005096/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Elliptic Integrates With Tempo, the Payments-First Blockchain18.3.2026 14:15:00 CET | Press release
Elliptic, the leader in digital asset decisioning, today announced full blockchain coverage for Tempo, the payments-first Layer-1 blockchain incubated by Stripe and Paradigm. With this integration, compliance and investigation teams gain full visibility into one of the most significant expansions of real-world financial activity onto blockchain infrastructure. "We're excited to have Elliptic providing compliance infrastructure on Tempo from day one. As payments move onchain at scale, builders and their customers need real-time tools to meet regulatory requirements without slowing down." – Nischay Upadhyayula, GTM, Tempo Tempo is a Layer-1 blockchain designed for real-world payments at scale, with sub-second finality and high throughput. Incubated by Stripe and Paradigm, Tempo is built for the transaction volumes that global commerce demands. Elliptic’s blockchain analytics platform is purpose-built to analyse on-chain data at this scale. “Tempo’s payment-specific blockchain infrastruct
RecVue Completes Acquisition of AiVidens18.3.2026 14:04:00 CET | Press release
Transaction advances RecVue RevOS into a unified revenue-to-cash Revenue Operating System RecVue, the leader in AI-powered billing and revenue management platforms for complex enterprise monetization, today announced it has completed the acquisition of AiVidens. By acquiring the cash management and collections platform, RecVue will enable enterprises to move beyond simple revenue automation to unify contract governance, billing, collections, revenue compliance, revenue sharing, and liquidity management all within a single revenue operating system. “This acquisition furthers our strategy to close the structural gap between revenue and cash,” said Nishant Nair, Founder and CEO of RecVue. “CFOs today are accountable not only for revenue accuracy, but for liquidity performance and working capital efficiency. With AiVidens, we are extending RevOS to connect commercial activity directly to cash realization.” While tasked with these widening responsibilities, enterprise CFOs struggle with dis
Blue Matter Launches People and Organization Practice to Help Biopharma Navigate Structural Shift18.3.2026 14:01:00 CET | Press release
Blue Matter today announced the launch of its People and Organization Practice, a dedicated capability designed to help life science companies build organizations that can perform through complexity - from enterprise transformation and M&A integration to talent strategy, learning, and workforce redesign. The launch reflects a central conviction: the biopharma industry is not experiencing a cyclical downturn but a structural shift. With more than 42,700 jobs cut across the sector in 2024–2025, unprecedented policy uncertainty, accelerating AI adoption, and intensifying portfolio pressure, organizations must transform all functions simultaneously, not sequentially, to remain competitive. A Proven Leader Across Transactions and Transformations Stacey Petrey brings more than 25 years of experience and a track record spanning more than 75 completed transactions. Stacey served as a Partner in PwC’s Deals practice where she focused on integrations, separations, value creation, and change mana
Deskpro Now Available on the AWS European Sovereign Cloud18.3.2026 14:00:00 CET | Press release
Deskpro has deployed its help desk platform on the AWS European Sovereign Cloud, extending access to AI-powered support for organizations that need to meet strict EU data residency and sovereignty requirements Today, Deskpro, provider of the secure AI-powered help desk platform, announced that it is a partner for the AWS European Sovereign Cloud, a new, independent cloud for Europe that is backed by strong technical controls, sovereign assurances, and legal protections designed to meet the needs of European governments and enterprises. Becoming an AWS European Sovereign Cloud partner strengthens Deskpro’s ability to support customers deploying environments within the AWS European Sovereign Cloud, and reinforces its commitment to supporting organizations for which data residency, governance, and regulatory alignment are non-negotiable. “European organizations face growing complexity around data sovereignty and regulatory compliance,” said Brad Murdoch, CEO of Deskpro. “By becoming an AW
Klarna Reaches 7 Million Consumers in France, Now Used by 1 in 7 Adults18.3.2026 14:00:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, today announced it has reached 7 million consumers in France, meaning 1 in 7 adults in the country now uses Klarna. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318130169/en/ Klarna reaches 7 million consumers in France. “Klarna reaching 7 million consumers in France is a significant milestone for us, and clear evidence of the shift away from high-interest consumer loans,” said Clémence Le Floch, Country Manager of Klarna in France. “The French are choosing new ways to pay, whether that's flexible payments or paying in full. Our growth reflects the strength of our merchant partnerships, the appeal of our digital banking offering, and the demand for smarter, more transparent financial tools.” France is also emerging as one of Klarna’s fastest-growing European markets in terms of app engagement. As of January 2026, the Klarna app reaches 2.9 million monthly a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom